

ADDENDUM to be inserted into NOFSA Guidelines.

On 1<sup>st</sup> September 2017 Servier South Africa announced the cessation of distribution of Protos<sup>®</sup> from September 2017. This announcement stated that this was a worldwide commercial and strategic decision taken for economic reasons and based on the following grounds:

- The restricted indication/limited use of Protos<sup>®</sup>
- The continuous decrease in patients treated with Protos<sup>®</sup>

It was stated that the decision was not related to a quality or safety issue.